104 related articles for article (PubMed ID: 24488143)
1. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.
Peddi PF; Hurvitz SA
Future Oncol; 2013 Mar; 9(3):319-26. PubMed ID: 23469968
[TBL] [Abstract][Full Text] [Related]
4. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases.
Torres S; Maralani P; Verma S
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25123575
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
[TBL] [Abstract][Full Text] [Related]
8. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
[TBL] [Abstract][Full Text] [Related]
9. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
Miller KD; Diéras V; Harbeck N; Andre F; Mahtani RL; Gianni L; Albain KS; Crivellari D; Fang L; Michelson G; de Haas SL; Burris HA
J Clin Oncol; 2014 May; 32(14):1437-44. PubMed ID: 24733796
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
[TBL] [Abstract][Full Text] [Related]
12. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Brodowicz T; Lang I; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Petruzelka L; Eniu A; Anghel R; Koynov K; Vrbanec D; Pienkowski T; Melichar B; Spanik S; Ahlers S; Messinger D; Inbar MJ; Zielinski C
Br J Cancer; 2014 Nov; 111(11):2051-7. PubMed ID: 25268370
[TBL] [Abstract][Full Text] [Related]
13. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.
Liu C; Yu J; Li H; Liu J; Xu Y; Song P; Liu Q; Zhao H; Xu J; Maher VE; Booth BP; Kim G; Rahman A; Wang Y
Clin Pharmacol Ther; 2017 May; 101(5):657-666. PubMed ID: 28182273
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.
Oude Munnink TH; Henstra MJ; Segerink LI; Movig KL; Brummelhuis-Visser P
Clin Pharmacol Ther; 2016 Apr; 99(4):419-31. PubMed ID: 26265133
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Cosson VF; Ng VW; Lehle M; Lum BL
Cancer Chemother Pharmacol; 2014 Apr; 73(4):737-47. PubMed ID: 24519752
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Krop IE; Modi S; LoRusso PM; Pegram M; Guardino E; Althaus B; Lu D; Strasak A; Elias A
Breast Cancer Res; 2016 Mar; 18(1):34. PubMed ID: 26979312
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Martín M; Loibl S; von Minckwitz G; Morales S; Martinez N; Guerrero A; Anton A; Aktas B; Schoenegg W; Muñoz M; Garcia-Saenz JÁ; Gil M; Ramos M; Margeli M; Carrasco E; Liedtke C; Wachsmann G; Mehta K; De la Haba-Rodriguez JR
J Clin Oncol; 2015 Mar; 33(9):1045-52. PubMed ID: 25691671
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
